MA53551B1 - Dosage nocturne chronique de lasmiditan pour la prévention de la migraine - Google Patents
Dosage nocturne chronique de lasmiditan pour la prévention de la migraineInfo
- Publication number
- MA53551B1 MA53551B1 MA53551A MA53551A MA53551B1 MA 53551 B1 MA53551 B1 MA 53551B1 MA 53551 A MA53551 A MA 53551A MA 53551 A MA53551 A MA 53551A MA 53551 B1 MA53551 B1 MA 53551B1
- Authority
- MA
- Morocco
- Prior art keywords
- migraine
- prevention
- lasmiditan
- chronic
- night
- Prior art date
Links
- 230000002265 prevention Effects 0.000 title abstract 3
- 230000001684 chronic effect Effects 0.000 title abstract 2
- XEDHVZKDSYZQBF-UHFFFAOYSA-N lasmiditan Chemical compound C1CN(C)CCC1C(=O)C1=CC=CC(NC(=O)C=2C(=CC(F)=CC=2F)F)=N1 XEDHVZKDSYZQBF-UHFFFAOYSA-N 0.000 title abstract 2
- 229950009142 lasmiditan Drugs 0.000 title abstract 2
- 208000019695 Migraine disease Diseases 0.000 abstract 3
- 206010027599 migraine Diseases 0.000 abstract 3
- 238000002560 therapeutic procedure Methods 0.000 abstract 2
- 230000009977 dual effect Effects 0.000 abstract 1
- 230000000422 nocturnal effect Effects 0.000 abstract 1
- 238000009097 single-agent therapy Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Saccharide Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
La présente invention concerne l'utilisation nocturne chronique de lasmiditan pour la prévention de la migraine, en particulier de la migraine résistante à la thérapie, qui est définie ici comme migraine résistante à au moins deux régimes de traitement ou de prévention en monothérapie et/ou bithérapie préalables.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862726585P | 2018-09-04 | 2018-09-04 | |
| PCT/US2019/049340 WO2020051137A1 (fr) | 2018-09-04 | 2019-09-03 | Dosage nocturne chronique de lasmiditan pour la prévention de la migraine |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MA53551A MA53551A (fr) | 2022-01-12 |
| MA53551B1 true MA53551B1 (fr) | 2023-11-30 |
Family
ID=68051892
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA53551A MA53551B1 (fr) | 2018-09-04 | 2019-09-03 | Dosage nocturne chronique de lasmiditan pour la prévention de la migraine |
Country Status (36)
| Country | Link |
|---|---|
| US (1) | US12138254B2 (fr) |
| EP (2) | EP3846810B1 (fr) |
| JP (2) | JP7321256B2 (fr) |
| KR (1) | KR102649644B1 (fr) |
| CN (1) | CN112638383A (fr) |
| AU (3) | AU2019336667B2 (fr) |
| BR (1) | BR112021002945A2 (fr) |
| CL (1) | CL2021000529A1 (fr) |
| CO (1) | CO2021002766A2 (fr) |
| CR (1) | CR20210126A (fr) |
| DK (1) | DK3846810T3 (fr) |
| DO (1) | DOP2021000039A (fr) |
| EA (1) | EA202190440A1 (fr) |
| EC (1) | ECSP21015491A (fr) |
| ES (1) | ES2967665T3 (fr) |
| FI (1) | FI3846810T3 (fr) |
| HR (1) | HRP20231587T1 (fr) |
| HU (1) | HUE064519T2 (fr) |
| IL (1) | IL281208B2 (fr) |
| JO (1) | JOP20210033B1 (fr) |
| LT (1) | LT3846810T (fr) |
| MA (1) | MA53551B1 (fr) |
| MD (1) | MD3846810T2 (fr) |
| MX (1) | MX2021002474A (fr) |
| MY (1) | MY199662A (fr) |
| PE (1) | PE20211599A1 (fr) |
| PH (1) | PH12021550448A1 (fr) |
| PL (1) | PL3846810T3 (fr) |
| PT (1) | PT3846810T (fr) |
| RS (1) | RS64857B1 (fr) |
| SG (1) | SG11202101530PA (fr) |
| SI (1) | SI3846810T1 (fr) |
| TW (1) | TWI826514B (fr) |
| UA (1) | UA129587C2 (fr) |
| WO (1) | WO2020051137A1 (fr) |
| ZA (1) | ZA202100666B (fr) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ596161A (en) | 2009-04-02 | 2013-11-29 | Colucid Pharmaceuticals Inc | Composition of 2,4,6-trifluoro-n-[6-(1-methyl-piperidin-4-carbonyl)-pyridin-2-yl]-benzamide |
| EP3102564A4 (fr) | 2014-02-05 | 2017-10-18 | Merck Sharp & Dohme Corp. | Formulation de comprimé pour composés actifs vis-à-vis du cgrp |
| US12168004B2 (en) | 2014-02-05 | 2024-12-17 | Merck Sharp & Dohme Llc | Treatment of migraine |
| US12383545B1 (en) | 2018-06-08 | 2025-08-12 | Allergan Pharmaceuticals International Limited | Treatment of migraine |
| EP4188375A4 (fr) * | 2020-07-29 | 2024-07-24 | Allergan Pharmaceuticals International Limited | Traitement de migraine |
| AU2021409718A1 (en) | 2020-12-22 | 2023-07-13 | Allergan Pharmaceuticals International Limited | Treatment of migraine |
| MX2024003952A (es) | 2021-09-27 | 2024-05-27 | Allergan Pharmaceuticals Int Ltd | Combinación que comprende atogepant para tratar la migraña. |
Family Cites Families (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5023252A (en) | 1985-12-04 | 1991-06-11 | Conrex Pharmaceutical Corporation | Transdermal and trans-membrane delivery of drugs |
| US5011472A (en) | 1988-09-06 | 1991-04-30 | Brown University Research Foundation | Implantable delivery system for biological factors |
| US5385912A (en) | 1991-03-08 | 1995-01-31 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Multicyclic tertiary amine polyaromatic squalene synthase inhibitors |
| US5360735A (en) | 1992-01-08 | 1994-11-01 | Synaptic Pharmaceutical Corporation | DNA encoding a human 5-HT1F receptor, vectors, and host cells |
| US5698571A (en) * | 1994-10-05 | 1997-12-16 | Eli Lilly And Company | 5-HT1F mediated inhibition of neurogenic meningeal extravasation: a method for the treatment of migraine |
| US5521196A (en) | 1994-10-05 | 1996-05-28 | Eli Lilly And Company | 5-HT1F agonists for the treatment of migraine |
| US5521197A (en) | 1994-12-01 | 1996-05-28 | Eli Lilly And Company | 3-<1-alkylenearyl>-4-<1,2,3,6-tetrahydropyridinyl>-and 3-<1-alkylenearyl>-4-piperidinyl-1h-indoles: new 5-HT1F agonists |
| AU702322B2 (en) | 1995-03-20 | 1999-02-18 | Eli Lilly And Company | 5-substituted-3-(1,2,3,6-tetrahydropyridin-4-yl)- and 3-(piperidin-4-yl)-1h-indoles: new 5-ht1f agonists |
| AU7261196A (en) | 1995-10-10 | 1997-04-30 | Eli Lilly And Company | N-{2-substituted-3-(2-aminoethyl)-1h-indol-5-yl}-amides: new 5-ht1f agonists |
| US5708187A (en) | 1996-06-27 | 1998-01-13 | Eli Lilly And Company | 6-substituted-1,2,3,4-tetrahydro-9H-carbazoles and 7-substituted-10H-cyclohepta 7,6-B!indoles: New 5-HT1F agonists |
| EP0929299B1 (fr) | 1996-08-28 | 2003-10-08 | Eli Lilly And Company | 1,2,3,4-tetrahydro-2-dibenzofuranamines substitues et 2-aminocyclo-hepta(b)benzofuranes |
| WO1998015545A1 (fr) | 1996-10-08 | 1998-04-16 | Eli Lilly And Company | Nouveaux agonistes de la serotonine 5-ht¿1f? |
| ZA979961B (en) | 1996-11-15 | 1999-05-05 | Lilly Co Eli | 5-HT1F agonists |
| EP0875513A1 (fr) | 1997-04-14 | 1998-11-04 | Eli Lilly And Company | Composés hétéroaromatiques substitués agonistes du récepteur 5-HT1F |
| ID23053A (id) | 1997-06-04 | 2000-01-20 | Lilly Co Eli | Karboksamida yang digunakan sebagai agonis 5-ht <if> |
| US5905084A (en) | 1997-11-14 | 1999-05-18 | Eli Lilly And Company | 5-HTIF -agonists effective in treating migraine |
| US6528529B1 (en) | 1998-03-31 | 2003-03-04 | Acadia Pharmaceuticals Inc. | Compounds with activity on muscarinic receptors |
| WO2000000490A2 (fr) | 1998-06-26 | 2000-01-06 | Eli Lilly And Company | Agonistes de 5-ht¿1f? |
| DE69912279T2 (de) | 1998-06-30 | 2004-07-29 | Eli Lilly And Co., Indianapolis | 5-ht1f agonisten |
| AU1937300A (en) | 1998-12-11 | 2000-06-26 | Eli Lilly And Company | Indole derivatives and their use as 5-HT1F agonists |
| JP2002536434A (ja) | 1999-02-10 | 2002-10-29 | イーライ・リリー・アンド・カンパニー | ５−ｈｔ１ｆアゴニスト |
| US6777428B1 (en) | 1999-02-10 | 2004-08-17 | Eli Lilly And Company | 5-HT1f agonist |
| KR20010102355A (ko) | 1999-02-26 | 2001-11-15 | 피터 지. 스트링거 | 5-ｈｔ1ｆ 효능제 |
| KR100849981B1 (ko) | 2000-07-13 | 2008-08-01 | 메르크 파텐트 게엠베하 | 키랄 화합물 ｉ |
| US6650463B2 (en) | 2001-03-13 | 2003-11-18 | Seiko Epson Corporation | Electrophoretic display device |
| WO2003000245A1 (fr) | 2001-06-22 | 2003-01-03 | Poseidon Pharmaceuticals A/S | Composes destines a etre utilises dans des troubles associes a l'activite des mastocytes ou des basophiles |
| TWI263497B (en) | 2002-03-29 | 2006-10-11 | Lilly Co Eli | Pyridinoylpiperidines as 5-HT1F agonists |
| AU2003295782A1 (en) | 2002-11-22 | 2004-06-18 | Bristol-Myers Squibb Company | Pyridinyl, pyrimidinyl and pyrazinyl amides as potassium channel openers |
| GB0308186D0 (en) | 2003-04-09 | 2003-05-14 | Smithkline Beecham Corp | Novel compounds |
| MXPA05011223A (es) | 2003-04-18 | 2006-01-26 | Lilly Co Eli | Compuestos de (piperidiniloxi)fenilo, (piperidiniloxi)piridinilo, (piperidinilsulfanil)fenilo y (piperidinilsulfanil)piridinilo como agonistas 5-htif. |
| WO2004099127A1 (fr) | 2003-05-07 | 2004-11-18 | Novo Nordisk A/S | Composes utilises comme inhibiteurs de kinase |
| WO2005007621A2 (fr) | 2003-05-30 | 2005-01-27 | Rigel Pharmaceuticals, Inc. | Inhibiteurs de ligase d'ubiquitine |
| UA82711C2 (en) | 2003-09-12 | 2008-05-12 | Эли Лилли Энд Компани | Substituted 2-carbonylamino-6-piperidinaminopyridines and substituted 1-carbonylamino-3-piperidinaminobenzenes as 5-ht1f agonists |
| GB0325956D0 (en) | 2003-11-06 | 2003-12-10 | Addex Pharmaceuticals Sa | Novel compounds |
| GB0510143D0 (en) | 2005-05-18 | 2005-06-22 | Addex Pharmaceuticals Sa | Novel compounds A1 |
| WO2006048771A1 (fr) | 2004-11-04 | 2006-05-11 | Addex Pharmaceuticals Sa | Nouveaux derives de tetrazole utilises comme modulateurs allosteriques positifs des recepteurs de glutamate metabotropiques |
| CA2588517A1 (fr) | 2004-12-01 | 2006-06-08 | Devgen N.V. | Derives de thiazole substitue par du 5-carboxamido qui interagissent avec des canaux ioniques, en particulier avec des canaux ioniques de la famille de kv |
| KR20060067738A (ko) | 2004-12-15 | 2006-06-20 | 주식회사 대웅제약 | 바닐로이드 수용체의 길항제로서 강력한 진통효과를나타내는 신규한 ｎ-아릴아마이드 유도체 및 이를함유하는 약제학적 조성물 |
| US20060178349A1 (en) | 2005-01-24 | 2006-08-10 | Pozen Inc. | Compositions and therapeutic methods utilizing a combination of a 5-HT1F inhibitor and an NSAID |
| DE102005016634A1 (de) | 2005-04-12 | 2006-10-19 | Merck Patent Gmbh | Neuartige Aza-Hetercyclen als Kinase-Inhibitoren |
| KR100976063B1 (ko) | 2007-03-16 | 2010-08-17 | 동아제약주식회사 | 신규한 벤즈아미드 유도체 화합물 및 그의 제조방법 |
| NZ596161A (en) | 2009-04-02 | 2013-11-29 | Colucid Pharmaceuticals Inc | Composition of 2,4,6-trifluoro-n-[6-(1-methyl-piperidin-4-carbonyl)-pyridin-2-yl]-benzamide |
| WO2011123654A1 (fr) | 2010-04-02 | 2011-10-06 | Colucid Pharmaceuticals, Inc. | Compositions et méthodes de synthèse d'agonistes des récepteurs 5-ht1f dérivés de la pyridinoylpipéridine |
| JOP20190129B1 (ar) | 2016-12-06 | 2023-03-28 | Colucid Pharmaceuticals Inc | تركيبات وطرق تتعلق بمواد مساعدة لـ 5-ht1f من بيريدينويل بيبريدين |
| TWI754772B (zh) | 2017-09-06 | 2022-02-11 | 美商美國禮來大藥廠 | 用於治療偏頭痛之拉米迪坦(lasmiditan)與cgrp拮抗劑之組合療法 |
-
2019
- 2019-09-02 TW TW108131567A patent/TWI826514B/zh active
- 2019-09-03 FI FIEP19773583.0T patent/FI3846810T3/fi active
- 2019-09-03 MA MA53551A patent/MA53551B1/fr unknown
- 2019-09-03 US US17/271,950 patent/US12138254B2/en active Active
- 2019-09-03 PE PE2021000286A patent/PE20211599A1/es unknown
- 2019-09-03 IL IL281208A patent/IL281208B2/en unknown
- 2019-09-03 KR KR1020217005977A patent/KR102649644B1/ko active Active
- 2019-09-03 BR BR112021002945-1A patent/BR112021002945A2/pt unknown
- 2019-09-03 PL PL19773583.0T patent/PL3846810T3/pl unknown
- 2019-09-03 WO PCT/US2019/049340 patent/WO2020051137A1/fr not_active Ceased
- 2019-09-03 LT LTEPPCT/US2019/049340T patent/LT3846810T/lt unknown
- 2019-09-03 HU HUE19773583A patent/HUE064519T2/hu unknown
- 2019-09-03 ES ES19773583T patent/ES2967665T3/es active Active
- 2019-09-03 RS RS20231107A patent/RS64857B1/sr unknown
- 2019-09-03 UA UAA202100630A patent/UA129587C2/uk unknown
- 2019-09-03 CR CR20210126A patent/CR20210126A/es unknown
- 2019-09-03 MY MYPI2021001043A patent/MY199662A/en unknown
- 2019-09-03 DK DK19773583.0T patent/DK3846810T3/da active
- 2019-09-03 SI SI201930647T patent/SI3846810T1/sl unknown
- 2019-09-03 EP EP19773583.0A patent/EP3846810B1/fr active Active
- 2019-09-03 SG SG11202101530PA patent/SG11202101530PA/en unknown
- 2019-09-03 HR HRP20231587TT patent/HRP20231587T1/hr unknown
- 2019-09-03 AU AU2019336667A patent/AU2019336667B2/en not_active Ceased
- 2019-09-03 CN CN201980055464.3A patent/CN112638383A/zh active Pending
- 2019-09-03 EP EP23195738.2A patent/EP4279132A3/fr active Pending
- 2019-09-03 EA EA202190440A patent/EA202190440A1/ru unknown
- 2019-09-03 MD MDE20210640T patent/MD3846810T2/ro unknown
- 2019-09-03 MX MX2021002474A patent/MX2021002474A/es unknown
- 2019-09-03 JP JP2021512380A patent/JP7321256B2/ja active Active
- 2019-09-03 PT PT197735830T patent/PT3846810T/pt unknown
-
2021
- 2021-01-29 ZA ZA2021/00666A patent/ZA202100666B/en unknown
- 2021-02-25 JO JOJO/P/2021/0033A patent/JOP20210033B1/ar active
- 2021-03-01 CO CONC2021/0002766A patent/CO2021002766A2/es unknown
- 2021-03-02 PH PH12021550448A patent/PH12021550448A1/en unknown
- 2021-03-02 DO DO2021000039A patent/DOP2021000039A/es unknown
- 2021-03-03 CL CL2021000529A patent/CL2021000529A1/es unknown
- 2021-03-04 EC ECSENADI202115491A patent/ECSP21015491A/es unknown
-
2022
- 2022-12-22 AU AU2022291568A patent/AU2022291568A1/en not_active Abandoned
-
2023
- 2023-07-25 JP JP2023120471A patent/JP7543497B2/ja active Active
-
2025
- 2025-02-28 AU AU2025201479A patent/AU2025201479A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP4279132A3 (fr) | Dosage nocturne chronique de lasmiditan pour la prévention de la migraine | |
| EP3283169A4 (fr) | Utilisation d'anticorps anti-pacap et de leurs fragments de liaison à l'antigène pour le traitement, la prévention ou l'inhibition de la photophobie | |
| EP3830183A4 (fr) | Compositions à base de fucanes hautement purifiés et/ou modifiés pour le traitement d'adhérences fibreuses | |
| MA41932B1 (fr) | Méthodes de traitement ou de prévention de migraines | |
| MA44560B1 (fr) | Anticorps anti-cd38 spécifiques pour le traitement de cancers humains | |
| MA43828A (fr) | Agents thérapeutiques pour maladies neurodégénératives | |
| WO2004087649A3 (fr) | Antagonistes benodiazepine spirohydantoin des recepteurs de cgrp | |
| ATE394400T1 (de) | Bicyclische anilidspirohydantoine als cgrp- rezeptorantagonisten | |
| EP1605936A4 (fr) | Antagonistes du recepteur cgrp d'aryl spirohydantoine | |
| MA39342B2 (fr) | Anticorps il -21 | |
| MA34968B1 (fr) | Urées asymétriques et utilisations médicales de celles-ci | |
| MA52961A (fr) | Compositions et procédés pour la réduction ou le traitement d'une inflammation | |
| WO2020106358A8 (fr) | Nouveaux anticorps contre le virus zika et utilisations associées | |
| EP4353245A4 (fr) | Composition pour la prévention ou le traitement de maladies inflammatoires ou du cancer, comprenant des vésicules dérivées de bactéries leuconostoc | |
| MA34489B1 (fr) | Agonistes du récepteur a1 à l'adénosine destinés au traitement du glaucome et de l'hypertension oculaire | |
| EP3710015A4 (fr) | Utilisation d'agents srsf3 pour le traitement et/ou la prévention d'affections neurologiques, du cancer, d'infections bactériennes ou d'infections virales | |
| EP4181915A4 (fr) | Compositions pour le traitement de l'obésité | |
| EP3826633A4 (fr) | Compositions pour le traitement de l'hypertension | |
| WO2019017499A3 (fr) | Composition pharmaceutique | |
| FR3061021B1 (fr) | Antagoniste specifique de tlr4 dans le traitement du myelome multiple | |
| MA41311B1 (fr) | Peptides antagonistes du cgrp | |
| EP4238611A4 (fr) | Composition pour la prévention, l'amélioration ou le soulagement des symptômes menstruels | |
| MA55588A (fr) | Combinaison de nitazoxanide et d'elafibranor pour le traitement de maladies immunitaires ou d'une inflammation | |
| WO2018141313A3 (fr) | Utilisation de composés fgf-4 | |
| EP4205737A4 (fr) | Composition pour la prévention, l'amélioration ou le traitement de maladies inflammatoires ou de maladies immunitaires comprenant la gancaonine n en tant que principe actif |